| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5502047 | CURRAX | Treatment for insomnia |
Mar, 2013
(11 years ago) | |
| US5585115 | CURRAX | Pharmaceutical excipient having improved compressability |
Jan, 2015
(9 years ago) | |
| US6217909 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5725884 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5866166 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US6103219 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5948438 | CURRAX | Pharmaceutical formulations having improved disintegration and/or absorptivity |
Jan, 2015
(9 years ago) | |
| US6211229 | CURRAX | Treatment of transient and short term insomnia |
Feb, 2020
(4 years ago) | |
| US10653662 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US10238620 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9861607 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9486437 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9572814 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US10653660 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US11110074 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US7915307 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Aug, 2027
(3 years from now) | |
| US11234954 | CURRAX | Low-dose doxepin for treatment of sleep disorders in elderly patients |
Jan, 2028
(3 years from now) | |
| US10548871 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US11096920 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9907780 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9107898 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2028
(4 years from now) | |
| US9532971 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Jun, 2029
(5 years from now) | |
| US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(6 years from now) | |
Silenor is owned by Currax.
Silenor contains Doxepin Hydrochloride.
Silenor has a total of 23 drug patents out of which 8 drug patents have expired.
Expired drug patents of Silenor are:
- US5502047
- US5585115
- US6217909
- US5725884
- US5866166
- US6103219
- US5948438
- US6211229
Silenor was authorised for market use on 17 March, 2010.
Silenor is available in tablet;oral dosage forms.
Silenor can be used as treatment of insomnia.
The generics of Silenor are possible to be released after 07 September, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
